Market Place
Sourcing Support
Artiva Biotherapeutics Reports Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Artiva Bio to Participate in Jefferies London Healthcare Conference
11 Nov 2024 //
GLOBENEWSWIRE
Artiva Biotherapeutics Appoints Alison Moore To Board
22 Oct 2024 //
GLOBENEWSWIRE
Artiva To Participate In Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Artiva Biotherapeutics Reports Q2 Financial Results and Business Highlights
29 Aug 2024 //
GLOBENEWSWIRE
Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq
19 Jul 2024 //
FIERCE BIOTECH
Artiva Biotherapeutics Prices Upsized $167 Million IPO
18 Jul 2024 //
GLOBENEWSWIRE
Actuate unveils modest $50M IPO to fund cancer drug trials
17 Jul 2024 //
FIERCE BIOTECH
Artiva sets out $135M IPO plans to push NK cell therapy through trials
15 Jul 2024 //
FIERCE BIOTECH
Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy
01 Jul 2024 //
FIERCE BIOTECH
Artiva Readies for Growth: New CFO, COO Appointments
25 Apr 2024 //
BUSINESSWIRE
Artiva Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
22 Feb 2024 //
BUSINESSWIRE
Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023
08 Nov 2023 //
BUSINESSWIRE
Artiva Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate
16 Aug 2023 //
BUSINESSWIRE
Artiva boasts early NK cell therapy results, giving lifeline to partner Affimed
26 May 2023 //
ENDPTS
Artiva Presents Initial Data from First-in-Human Phase 1/2 Trial of AB-101
25 May 2023 //
BUSINESSWIRE
Artiva Announces of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101
26 Apr 2023 //
BUSINESSWIRE
Artiva Biotherapeutics Presents Preclinical Data for AB-101
10 Nov 2022 //
BUSINESSWIRE
Affimed & Artiva Announce Partnership to Combo Therapy of Innate Cell Engager
04 Nov 2022 //
AFFIMED
Artiva Announces Abstract Accepted for Presentation at the 64th ASH
03 Nov 2022 //
BUSINESSWIRE
An NK cell therapy biotech pulls IPO ambitions weeks after 2nd trial clearance
02 Nov 2022 //
ENDPTS
Artiva Announces AB-101 Abstract Accepted for Presentation at SITC
05 Oct 2022 //
BUSINESSWIRE
Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201
20 Sep 2022 //
BUSINESSWIRE
Artiva Bio Celebrates Official Opening of San Diego Corporate Headquarters
13 Jun 2022 //
BUSINESSWIRE
Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer
06 Jun 2022 //
BUSINESSWIRE
Artiva Biotherapeutics Appoints Board of Directors and Clinical Advisory Board
05 May 2022 //
BUSINESSWIRE
Merck extends pact with Artiva; Regeneron-allied biotech pencils in $15M IPO
11 Apr 2022 //
ENDPTS
Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting
21 Oct 2021 //
BUSINESSWIRE
Artiva Biotherapeutics Demonstrates Commitment, Corporate Social Responsibility
30 Sep 2021 //
BUSINESSWIRE
Merck NK cell ally Artiva splashes out on new digs in San Diego
12 Aug 2021 //
FIERCE BIOTECH
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility
12 Aug 2021 //
BUSINESSWIRE
Artiva to open a manufacturing site to take NK cell operation to the next level
12 Aug 2021 //
ENDPTS
NK cell therapy player Artiva makes some more noise, pulling in $120M Series B
26 Feb 2021 //
ENDPTS
Artiva, fresh from Merck pact, raises $120M for NK therapy R&D
26 Feb 2021 //
FIERCEBIOTECH
Dean Li kicks off Merck`s post-Roger Perlmutter era by teaming with Artiva
28 Jan 2021 //
ENDPTS
With latest deal, Merck wades into cell therapy for cancer
28 Jan 2021 //
BIOPHARMADIVE
Dean Li kicks off Merck`s post-Roger Perlmutter era by teaming with Artiva
28 Jan 2021 //
ENDPTS
Artiva Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101
07 Dec 2020 //
BUSINESSWIRE
Artiva Biotherapeutics Announces FDA Allowance of IND Trials of AB-101
07 Dec 2020 //
BIOSPACE
